Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02926196 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab(A-Brave) | completed | Phase 3 | 474 | Istituto Oncologico Veneto IRCCSOTHER | 2 |
| Dec 12, 2025 |
| clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT03013010 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy(PREACT) | completed | Phase 3 | 204 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | completed | Phase 3 | 371 | Astellas Pharma Global Development, Inc.INDUSTRY | 14 | Dec 4, 2025 | clinicaltrials |
| NCT03808805 | Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms(APHYPAP) | completed | Phase 3 | 63 | University Hospital, BrestOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04620369 | Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy | completed | Phase 3 | 106 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma(ZUMA-7) | completed | Phase 3 | 359 | Kite, A Gilead CompanyINDUSTRY | 14 | Dec 1, 2025 | clinicaltrials |
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02442375 | Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity(UPGRADE-RT) | completed | Phase 3 | 300 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | completed | Phase 3 | 298 | NovoCure GmbHINDUSTRY | 15 | Oct 31, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY | 33 | Oct 30, 2025 | clinicaltrials |
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | completed | Phase 3 | 1,174 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Oct 29, 2025 | clinicaltrials |
| NCT03136445 | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia(TREATT) | completed | Phase 3 | 616 | NHS Blood and TransplantOTHER_GOV | 2 | Oct 28, 2025 | clinicaltrials |
| NCT03269994 | Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? | completed | Phase 3 | 967 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 21, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 684 | BeiGeneINDUSTRY | 11 | Oct 14, 2025 | clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma(SOMAPROTECT01) | completed | Phase 3 | 179 | Hospices Civils de LyonOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 30, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03367572 | Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer | completed | Phase 3 | 1,363 | University of Rochester NCORP Research BaseOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04487067 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista(AMETHISTA) | completed | Phase 3 | 152 | Hoffmann-La RocheINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06341998 | Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children(SCRRYST) | completed | Phase 2 / Phase 3 | 32 | Shandong First Medical UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer(VITAL) | completed | Phase 3 | 913 | SanofiINDUSTRY | 32 | Sep 10, 2025 | clinicaltrials |
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT00930033 | Clinical Trial to Assess the Importance of Nephrectomy(CARMENA) | completed | Phase 3 | 452 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00186888 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | completed | Phase 3 | 107 | St. Jude Children's Research HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 498 | Janssen Research & Development, LLCINDUSTRY | 15 | Aug 29, 2025 | clinicaltrials |
| NCT00278408 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 700 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 4 | Aug 26, 2025 | clinicaltrials |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | completed | Phase 3 | 706 | Incyte CorporationINDUSTRY | 23 | Aug 24, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | completed | Phase 2 / Phase 3 | 130 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01951482 | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02066454 | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs(MYELAXAT) | completed | Phase 3 | 108 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2025source: clinicaltrials